FCP
IDXX icon

Fidelis Capital Partners’s Idexx Laboratories IDXX Stock Holding History

Fidelis Capital Partners’s Portfolio IDXX Stock Details IDXX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$361K Sell
685
-149
-18% -$83.6K 0.02% 399
2026
Q1 		$469K Buy
834
+78
+10% +$50K 0.03% 330
2025
Q4 		$511K Sell
756
-41
-5% -$27.9K 0.04% 304
2025
Q3 		$509K Buy
797
+20
+3% +$12.1K 0.04% 301
2025
Q2 		$485K Buy
777
+27
+4% +$12.9K 0.04% 268
2025
Q1 		$328K Buy
750
+18
+2% +$7.82K 0.03% 301
2024
Q4 		$343K Sell
732
-134
-15% -$58.8K 0.03% 318
2024
Q3 		$397K Sell
866
-22
-2% -$10.7K 0.05% 270
2024
Q2 		$415K Sell
888
-89
-9% -$44.7K 0.06% 236
2024
Q1 		$528K Buy
977
+59
+6% +$32.2K 0.08% 204
2023
Q4 		$510K Buy
918
+347
+61% +$163K 0.11% 167
2023
Q3 		$250K Sell
571
-9
-2% -$4.49K 0.09% 224
2023
Q2 		$291K Buy
580
+44
+8% +$21.1K 0.11% 204
2023
Q1 		$262K Buy
+536
New +$257K 0.11% 201

Other funds holding IDXX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Fidelis Capital Partners's IDXX Position: Q2 2026 in Review

Fidelis Capital Partners reduced its Idexx Laboratories (IDXX) stake by 18% in Q2 2026, selling an estimated $83.6K and leaving 685 shares worth $361K. The position accounts for 0.02% of the portfolio, ranked #399.

Fidelis Capital Partners first reported a position in IDXX in Q1 2023 and has held it in 14 quarters since. The position peaked at $528K in Q1 2024. 1,306 funds tracked by Wall St. Rank hold IDXX as of Q2 2026.

  • Fidelis Capital Partners held 685 shares of Idexx Laboratories worth $361K as of Q2 2026.
  • Fidelis Capital Partners sold 149 Idexx Laboratories shares in Q2 2026, an estimated $83.6K.
  • Idexx Laboratories made up 0.02% of Fidelis Capital Partners's portfolio in Q2 2026, its #399 holding.
  • Fidelis Capital Partners first reported a position in Idexx Laboratories in Q1 2023 and has held it in 14 quarters since.
  • Fidelis Capital Partners's Idexx Laboratories position peaked at $528K in Q1 2024.
  • 1,306 funds tracked by Wall St. Rank held Idexx Laboratories as of Q2 2026.

Based on Fidelis Capital Partners's 13F filing for Q2 2026, filed 13 Aug 2026.